Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-12

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chemotherapy induced nausea and vomiting are common adverse events related to oncologic treatments. It can have deleterious effect on patients' quality of life and could lead to dose reductions and/or discontinuation of treatment. This study aims to quantify the prevalence of nausea and vomiting induced by highly emetogenic chemotherapy in patients who had adequate antiemetic prophylaxis, also to describe the epidemiologic profile and identify predisposing factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting

NCT01993381

Chemotherapy-induced Nausea and Vomiting

UNKNOWN

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

NCT00211601

Chemotherapy Induced Nausea and Vomiting

COMPLETED NA

Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting

NCT01581918

Chemotherapy-induced Nausea and Vomiting

UNKNOWN PHASE2

Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer

NCT00416689

Breast Cancer Lung Cancer Nausea and Vomiting

COMPLETED

Prevalence of Delayed Chemotherapy Associated Nausea

NCT04342780

Chemotherapy-induced Nausea and Vomiting

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will track patients in the first and second cycles of chemotherapy. Information regarding comorbidities, medical history and sociodemographic characteristics will be collected. The impact of nausea and vomiting induced by the treatment on patient's quality of life will be evaluated using the questionnaire Functional Living Index-Emesis - FLIE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy-induced Nausea and Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer Patients Exposed to Highly Emetogenic Chemotherapy

Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis.

Quality-of-life assessment

Intervention Type OTHER

Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quality-of-life assessment

Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histological confirmation of cancer;
* Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis;
* No previous cancer treatment for the current diagnosis (excluding surgery);

Exclusion Criteria

* Patients who have an inability to answer the questionnaire, due to lack of discernment to answer the questions reliably;
* Patients who report vomiting during the 24 hours prior to the first cycle of chemotherapy treatment;
* Patients who have a disease or condition that could cause emesis (ie, metastasis in the central nervous system, gastrointestinal obstruction or metabolic and electrolyte imbalances);
* Patients using opioids or illicit drugs;
* Alcoholism;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No